What's In Store For You? 

Advanced Therapies Europe 2025 is built for biotechs ready to scale.
This is your platform to fast-track commercialisation, secure the right funding, and build strategic partnerships that turn innovation into impact.

Connect directly with VCs, fund managers, and pharma partners actively investing in advanced therapies.

Stay ahead with insights on regulatory strategy, market access, and the latest breakthroughs shaping the CGT landscape.

Find CDMOs, tech enablers, and solution providers to help you accelerate development and reach patients faster.

Apply to attend

Discover key themes and must attend sessions

  • Avoid Trial Pitfalls - Hear how peers are overcoming recruitment and endpoint challenges in rare diseases and oncology to help you avoid common pitfalls and accelerate trial timelines.

  • Understand Investor Priorities - Learn what VCs are prioritising in the current environment (clinical de-risking, platform breadth, co-development deals). Tailor your pitch and close faster.

  • Build Strategic Partnerships - Book 1-2-1 meetings with investors, pharma BD, and CDMOs and open the door to critical relationships you need for your next milestone.

  • Panel Session: The state of the CGT industry & turning the future into action

  • Panel Session: Pharma & biotech partnerships – What makes a deal actually happen?

  • Panel Session: CGT regulations uncovered: New rules, new realities

  • Panel Session: From discovery to development – Creating realistic CGT timelines

  • Roundtable Session: Intellectual property and commercialisation strategies

  • And a lot more...


    View the agenda

Your Personalised Itinerary

09:55
  1. Plenary

    Deep dive into the regulatory framework that governs CGT across major rejoins, focusing on recent updates, new legislation and how companies can navigate the changing landscape.

10:25
  1. Plenary
    A conversation with key patient advocates and organisations to highlight the importance of patient engagement, access, and ensuring therapies meet real-world needs in CGT.
11:30
    • R&D, clinical innovation & translation
    Theatre 1
    • Cutting edge developments in CRISPR, gene editing and cell engineering
    • The next wave of in vivo and ex vivo gene therapies
    • What breakthroughs are expected to reshape the industry?
    • Manufacturing, scale up & commercial strategy
    Theatre 2
    • As the pressure mounts to deliver advanced therapies faster, cheaper, and closer to the patient, decentralised manufacturing is stepping into the spotlight. But does breaking away from centralised models really deliver on cost? 

    • This panel dives into the economic realities behind the decentralisation trend. Are localised manufacturing hubs the answer to cutting costs, or do they introduce new layers of complexity and hidden spend? From infrastructure investments to regulatory headaches, we’ll separate financial fact from fiction and explore whether decentralisation is a bold leap forward or an expensive detour. 

12:25
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
12:50
    • R&D, clinical innovation & translation
    Theatre 1
    • Scientific advances and key breakthroughs.
    • Safety, efficacy, and regulatory challenges.
    • Investment trends and commercialisation potential.
    • Manufacturing, scale up & commercial strategy
    Theatre 2
    • Balancing technical and financial realities in manufacturing
    • When to invest in infrastructure vs outsourcing
    • The role of automation in optimising CMC process
14:30
    • R&D, clinical innovation & translation
    Theatre 1
    • How startups secure investment before reaching human trials 

    • strategic and tactical guidance on how to secure the right funding at the right time, from seed rounds through Series A 

    • Investor insights into due diligence, risk mitigation and valuation and what good really looks like  

    • Manufacturing, scale up & commercial strategy
    Theatre 2
    • Transitioning from academic proof of concept to market-ready product 

    • Why biotech teams must integrate CMC, regulatory and pharmacology early 

    • Avoiding pitfalls of overselling and overpromising 

15:05
    • R&D, clinical innovation & translation
    Theatre 1
    • Why characterisation and analytics remain a major hurdle. 

    • Collaborative approaches to tackling technical challenges 

    • Best practices and emerging solutions. 

    • Manufacturing, scale up & commercial strategy
    Theatre 2
    Discuss the key challenges in patient-centric manufacturing, focusing on ensuring timely delivery of therapies, managing logistics, and addressing issues related to personalised treatments, from patient selection to product delivery. 
15:40
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
16:00
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
11:30
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
11:50
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
12:15
    • R&D, clinical innovation & translation
    Theatre 1
    • Best practices for early interactions with EMA, FDA, MHRA etc. 

    • How proactive regulatory engagement reduces delays and de-risk trials 

    • Lessons learned from companies that successfully navigated approval 

     

    • Manufacturing, scale up & commercial strategy
    Theatre 2
    • Explore strategies for securing reimbursement and market access for cell and gene therapies, focusing on pricing, HTAs, and policy advocacy to ensure patient access. 

14:00
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
14:20
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
15:15
  1. Plenary

    AI is everywhere, but in CGT, real deployment remains limited. This session goes beyond the buzz to explore the tangible opportunities, early wins, and critical barriers to broader adoption. 

    We’ll look at where AI is beginning to make a difference and what’s still needed to move from isolated pilots to real impact. What kind of data, infrastructure, and cross-functional collaboration will unlock AI’s full potential in CGT? 

16:00
  1. Plenary
    As we wrap up two days of deep discussions on the current state of the European CGT landscape, this final panel will chart the path ahead. Which steps must Europe take to remain competitive and lead the way in the next 5–10 years? Each panellist will share their key takeaways from the last two days, reflecting on the insights, challenges, and opportunities discussed. 

Discover Advanced Therapies Week as a biotech

Accelerate your path from bench to bedside at Advanced Therapies Europe.
Join the leading event that brings together the full advanced therapies ecosystem — from regulators and investors to CDMOs, pharma, and academic pioneers. Whether you're seeking funding, strategic partners, or regulatory insight, this is your chance to fast-track development, scale smarter, and commercialise with confidence.

Content Packed Agenda

Gain insights, meet investors, and accelerate your path to commercialization.

State of the Art Networking

Discover promising companies, network with peers, and explore new opportunities.

Industry Leading Vendors

Share findings, learn from experts, and showcase your contributions to the field.

Exclusive Access to Investors

Connect with potential clients and showcase solutions that drive industry progress.

Who Might You Find On the Show Floor?

Sample Attendee List Current Exhibitor List

500+
Attendees
40+
Companies
150+
Speakers
170+
Therapeutic Developers

 

  • "What an incredible few days at the ATE conference by Phacilitate! Grateful for the power of my network and the opportunity to meet so many familiar faces while growing it further.”
    Head of Business Development: Cell Therapy and Laboratory Services | Cell and Gene Therapy
  • “Impactful moments and connections.”
    Director Global Cell and Gene Therapies Portfolio Management | EMBA | Deep Tech
  • “Already having fantastic conversations here at ATE24 in Lisbon.”
    Experienced Leader in Cell and Gene Therapy Business and Commercial Strategy